Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

The market has climbed by 5.8% over the past week, and is up 4.8% over the past year, with earnings expected to grow by 14% per annum in the coming years. Though the term 'penny stock' might sound ...

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed ...

Welcome to CureVac fourth-quarter and full year 2024 financial results and business update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...

CureVac (CVAC) has reported its fourth quarter 2024 financial results, generating mixed reactions from investors as the company balances ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac.

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...

Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025 Filed IND and CTA submissions for ...

Greetings. Welcome to CureVac Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...